Silence Therapeutics PLC Sponsored ADR SLN 深 滬
已收盤 06-18 16:00:00 美东时间
6.93
+0.170
+2.51%
華盛通- 最 高7.00
- 今 開6.82
- 成交量 38.29万股
- 最 低 6.52
- 昨 收 6.76
- 總市值 3.27亿
- 52周最高 8.40
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 4.19
- 委 比 50.00%
- 總股本 4723.46万
- 歷史最高 35.00
- 量 比 1.01
- 振 幅 7.10%
- 歷史最低 1.97
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating Divesiran In 21 Phlebotomy-Dependent Patients With Polycythemia Vera At EHA 2026 Annual Congress.
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final dose Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in Augu...
06-12 01:20
Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.
Silence Therapeutics shares are trading lower after the company reported worse-...
05-08 00:48
Silence Therapeutics Q1 EPS $(0.11) Beats $(0.21) Estimate, Sales $422.000K Miss $2.439M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 45 percent increase over losses of $(0.20) per share from
05-07 20:20
Why Urgent.ly Shares Are Trading Higher By Around 159%; Here Are 20 Stocks Moving Premarket
Urgent.ly shares surged in pre-market trading after agreement to be acquired by Agero for $5.50 per share. Also reported better-than-expected Q4 results.
03-16 17:39
Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.
Silence Therapeutics shares are trading lower after the company reported worse-...
03-06 00:12
Silence Therapeutics Q4 Earnings Assessment
Silence Therapeutics (NASDAQ:SLN) released its Q4 earnings on Thursday, March 5...
03-05 20:58
Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.43) by 37.21 percent. This is a 200 percent decrease over earnings of $0.27 per share from
03-05 20:57
Silence Therapeutics President And CEO Craig Tooman Steps Down; Chairman Iain Ross Named Interim Leader
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the
2025-12-15 21:17
Silence Therapeutics Q3 EPS $(0.15) Beats $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 46.43 percent. This is a 40 percent increase over losses of $(0.25) per share from
2025-11-06 20:39
